Northwestern University scientists have developed an injectable nanomaterial, dubbed “dancing molecules”, that cross the blood-brain barrier and shield brain tissue from post-stroke damage. Published January 2026 in Neurotherapeutics, the therapy uses tiny, constantly moving molecular assemblies, known as supramolecular therapeutic peptides (STPs), delivered intravenously that self-organize into nanofibers inside injured brain tissue. In mice, a single IV dose given after blood flow was restored significantly reduced inflammation, tissue death, and harmful immune response with no observed toxicity.

In July 2025, Amphix Bio, the company behind the treatment, posted on LinkedIn: “We are thrilled to announce the FDA has granted an Orphan Drug Designation to AMFX-200, our lead candidate based on the Supramolecular Therapeutic Peptide (STP) platform, for the treatment of acute spinal cord injury. This will accelerate our efforts to bring this novel neuro-regenerative therapeutic to the clinic.”*

* I cannot find any record of human trials of this stroke treatment, as of yet. Additionally, key limitations remain, as results are preclinical only, dosing must be precise to prevent blood clotting, and long-term human safety is unproven.